期刊文献+

硬脂胺-异硫氰基荧光素嫁接物的合成工艺研究及其应用评价

Optimization of ODA-FITC Conjugate Process and Its Application
原文传递
导出
摘要 目的:探究硬脂胺-异硫氰基荧光素嫁接物的最优合成工艺,并对其进行应用评价。方法:以硬脂胺和异硫氰基荧光素为原料,通过偶合反应合成得到脂质材料硬脂胺-异硫氰基荧光素嫁接物,利用薄层色谱法监测反应过程;通过核磁共振对嫁接产物进行结构确证,并以溶剂、时间、温度以及投料比为考察因素,以产率为指标,得到最优合成工艺。并将合成的硬脂胺-异硫氰基荧光素嫁接物用于标记脂质纳米粒,以结扎肠循环模型考察纳米粒在小肠的吸收分布情况对其进行应用评价。结果:当反应溶剂为无水乙醇,硬脂胺和异硫氰基荧光素的反应摩尔比为2∶1,60℃搅拌反应48 h后异硫氰基荧光素与硬脂胺反应最完全,产率较高,可达(72.0±3.9)%,并能较准确地评价其标记的纳米粒在肠绒毛吸收分布情况。结论:优化后合成处方工艺反应完全,得率高;方法操作简单,重复性好;合成的硬脂胺-异硫氰基荧光素嫁接物可用于直观评价纳米粒的体内外情况。 Objective: To optimize the synthesis process of octadecylamine-fluorescein isothiocynate( ODA-FITC),and evaluate its application. Method: ODA-FITC was synthesized by coupling reaction with ODA and FITC as raw materials,and the reaction process was monitored by thin layer chromatography. Its structure was verified by nuclear magnetic resonance spectroscopy, and the optimum synthesis process was obtained with the solvent,time,temperature and feed ratio as the investigation factors and with yield as the indicator. ODA-FITC was then used as a fluorescence marker for nanostructured lipid carriers( NLC) by solvent diffusion method. The ligated intestinal circulation model was established to observe the absorption and distribution of NLC in small intestine and evaluate its application. Result: The optimum reaction conditions were as follows: the molar ratio of ODA to FITC was 2 ∶ 1, the solution was anhydrous ethanol, after reaction for 48 h at 60 ℃. Under such conditions,the yield was high, reaching( 72. 0 ± 3. 9) %, and the absorption and distribution of its marked nanoparticles in intestinal villus can be accurately evaluated. Conclusion: The synthesis method has complete reaction and high yield, with simple operation and high repeatability. Synthetic ODA-FITC can be used to intuitively evaluate the in vitro and in vivo conditions of nanoparticles.
作者 陈晓晓 尹丽娜 张雅雯 周云琍 王胜浩 梁泽华 CHEN Xiao-xiao;YIN Li-na;ZHANG Ya-wen;ZHOU Yun-li;WANG Sheng-hao;LIANG Ze-hua(College of Pharmaceutical Science,Zhejiang Chinese Medical University,Hangzhou 310053,China;Zhejiang Academy of Medical Sciences,Hangzhou 310013,China)
出处 《中国实验方剂学杂志》 CAS CSCD 北大核心 2018年第19期56-60,共5页 Chinese Journal of Experimental Traditional Medical Formulae
基金 浙江省自然科学基金项目(LQY18H3000002) 浙江省医药卫生科技计划项目
关键词 异硫氰基荧光素 硬脂胺-异硫氰基荧光素嫁接物 薄层色谱 小肠微绒毛吸收 fluorescein isothiocynate ODA-FITC TLC absorption by intestinal microvillus
  • 相关文献

参考文献5

二级参考文献34

  • 1孙铭,杜智,孙洪范,方淑昌,周立波,毕海英,宋继昌.胰岛素纳米粒子缓释制剂的实验研究[J].生物医学工程与临床,2001,5(4):188-192. 被引量:3
  • 2徐元龙,李学明,张琪,蔺胜照.固体脂质纳米粒的研究新进展[J].中国新药杂志,2005,14(7):838-843. 被引量:17
  • 3李宝光,陶秀花,倪国平,黄冬华,宋小民.扫描像素法测定植物叶面积的研究[J].江西农业学报,2006,18(3):78-81. 被引量:34
  • 4杨豪,乔卫平,郑福增.马钱子及其制剂治疗类风湿关节炎研究进展[J].中医正骨,2007,19(4):71-73. 被引量:8
  • 5Wolfang M, Karsten M. Solid lipid nanoparticles production, characterization and applications[J]. Adv Drug Deli Revs, 2001,47 (2-3):165.
  • 6Yang SC, Lu LF, Cai Y. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain[J]. J Controlled Release, 1999,59 (3) :299.
  • 7Muller PH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art [J] . Eur J Pharm Biopharm, 2000,50 (1):161.
  • 8Yang SC, Zhu JB, Lu Y. Body distribution of camptothecin solid lipid nanoparticles after oral administration [J]. Pharm Res, 1999, 16 (5):751.
  • 9Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles[J]. Int J Pharm ,2001,214(1-2) :9.
  • 10Roberta C, C asco MR, Patrizia C.Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin [J]. Int J Pharm, 2002,238 (1 -2):241.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部